The term castrate resistant prostate cancer (CRPC) was initially proposed by the Prostate
Cancer Working Group 2 in 2008 to define the state of clinical and/or biochemical …

Here we aim to provide updated guidance and standards for the indication, acquisition, and
interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics …

Photoacoustic imaging (PAI) of biological tissue has been a fast developing biomedical multi-
wave imaging modality, after its introduction in the mid90s. PAI couples laser excitation to …

Biochemical recurrence (BCR) is a clinical challenge in prostate cancer (PCa) patients, as
recurrence localization guides subsequent therapies. The use of PET with prostate-specific …

Background Prostate-specific membrane antigen (PSMA) imaging has been suggested as
highly sensitive modality for detection of metastases in patients with biochemically recurrent …

Prostate carcinoma is a highly prevalent biologically and clinically diverse disease,
generally associated with a consistent elevation of prostate-specific antigen levels …

Background: prostate-specific membrane antigen (PSMA) ligand PET has been recently
incorporated into international guidelines for several different indications in prostate cancer …

PURPOSE Intrapatient treatment response heterogeneity is under-recognized. Quantitative
total bone imaging (QTBI) using 18F-NaF positron emission tomography/computed …

PSMA-targeted PET/CT is currently considered the most effective non-invasive diagnostic
technique for imaging PSMA-positive lesions in prostate cancer (PC), and its introduction …

Prostate cancer is the second most common cause of cancer-related mortality in men. In
patients undergoing a failure after radical treatment, one of the therapeutic option is …